THE ARIZONA STATE BOARD OF PHARMACY HELD A REGULAR MEETING
JANUARY 25, 2017 MINUTES FOR REGULAR MEETING (MEETING FOR
JANUARY 26, 2017 WAS CANCELLED)

AGENDA ITEM 1 – Call to Order – January 25, 2017

President Kennedy convened the meeting at 8:30 A.M. and welcomed the audience to the meeting.

The following Board Members were present: President Darren Kennedy, Michael Blaire, Kevin Dang, Kyra Locnikar, Dennis McAllister, Reuben Minkus, Doug Skvarla, Kristen Snair, and Tom Van Hassel. The following staff members were present: Compliance Officers Tom Petersen, Steve Haiber, Karol Hess, Sandy Sutcliffe and Dennis Waggoner, Drug Inspectors Melanie Thayer and Joshlyn Noble, Executive Director Kamlesh Gandhi, Deputy Director Cheryl Frush, and Assistant Attorney General Jeanne Galvin.

AGENDA ITEM 2 – Reappointment of Board Members

President Kennedy announced the following reappointments of Board Members:

1. Reuben Minkus – Public Member
2. Doug Skvarla – Pharmacist Member

AGENDA ITEM 3 – Declaration of Conflicts of Interest

Due to having a “substantial interest” in the matter, Mr. Skvarla recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 16, Schedule W, Conference for Complaint #4505.

Due to having a “substantial interest” in the matter, Mr. Skvarla recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 18, Schedule Y, Complaint #4527.

Due to having a “substantial interest” in the matter, Mr. Skvarla recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 19, Thomas Goebig, Stipulation to Continue Hearing for Case No. 17-0005-PHR.

Due to having a “substantial interest” in the matter, Mr. Skvarla recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 20, Thomas Goebig, Case No. 17-0005-PHR, Vacation of Hearing for January 23, 2017.
Due to having a “substantial interest” in the matter, Mr. Skvarla recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 21, Schedule Z, Hearing for Thomas Goebig, Case No. 17-0005-PHR.

Due to having a “substantial interest” in the matter, Mr. Skvarla and Mr. Kennedy were recused from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 30, Vanessa Thompson, Review of Evaluation and Pending Technician Trainee Application.

Due to having a “substantial interest” in the matter, Mr. Kennedy recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 6, Schedule N, Resident Pharmacy Permit for Walgreens Mail Service.

Due to having a “substantial interest” in the matter, Mr. Kennedy recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 12, Schedule T, Pharmacy Technician Application for Stephanie McFarland.

Due to having a “substantial interest” in the matter, Mr. Kennedy recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 12, Schedule T, Pharmacy Technician Application for Samantha Kurowski.

Due to having a “substantial interest” in the matter, Mr. Kennedy recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 12, Schedule T, Pharmacy Technician Application for Sarah Schwarz.

Due to having a “substantial interest” in the matter, Mr. Kennedy recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 12, Schedule T, Pharmacy Technician Application for Kevin Keck.

Due to having a “substantial interest” in the matter, Mr. Kennedy recused himself from participating under Arizona’s conflict of interest laws in the review, discussion, and proposed actions concerning Agenda Item 17, Consent Agreement for Marilyn Myers.

**AGENDA ITEM 4— Approval of Minutes**

Following a review of the minutes and an opportunity for questions and **on motion by Mr. Blaire and seconded by Mr. Van Hassel**, the Board Members unanimously approved the minutes for the Regular Meeting and Executive Session held on November 16 and 17, 2016.

Following a review of the minutes and an opportunity for questions and **on motion by Mr. Van Hassel and seconded by Dr. Dang**, the Board Members unanimously approved the minutes for the Special Telephonic Meeting for the Summary Suspension of Thomas Goebig’s Pharmacist license. Mr. Skvarala was recused and did not attend the meeting. Mr. Kennedy also did not attend the meeting.
AGENDA ITEM 5 – Consent Agenda
Items listed on the Consent Agenda were considered as a single action item by the Board Members. On motion by Mr. Van Hassel and seconded by Dr. Dang, the Board unanimously approved the following items listed on the Consent Agenda.

5. (1) Resident Pharmacy Permits – Schedule A

RESIDENT PHARMACY PERMITS

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bashas’ United Drug #110</td>
<td>1133 N. Ellsworth Rd., Mesa, AZ 85207</td>
<td>Bashas’ Inc.</td>
</tr>
<tr>
<td>Bashas’ United Drug #051</td>
<td>1122 N. Higley Rd., Mesa, AZ 85205</td>
<td>Bashas’ Inc.</td>
</tr>
<tr>
<td>The Core Institute Specialty Hospital</td>
<td>6501 N. 19th Ave., Phoenix, AZ 85015 (O)</td>
<td>Surgical Specialty Hospital of Arizona, LLC</td>
</tr>
</tbody>
</table>

(O) = Ownership Change

5. (2) Non-Resident Pharmacy Permits (Out of State) – Schedule B

NON-RESIDENT PHARMACY PERMITS

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical Specialties Express</td>
<td>150 Cleveland Rd, Suite B, Bogart, GA 30622 (O)</td>
<td>Pharmaceutical Specialties, LLC</td>
</tr>
<tr>
<td>The Farmacy</td>
<td>18484 Preston Rd., Suite 112, Dallas, TX 75252</td>
<td>Elixir Consulting, LLC</td>
</tr>
<tr>
<td>Carepoint Pharmacy</td>
<td>1801 S. Dairy Ashford Rd. #127, Houston, TX 77077</td>
<td>Carepoint Texas, LLC</td>
</tr>
<tr>
<td>StarCare Pharmacy</td>
<td>321 N. Preston Rd., Suite B, Prosper, TX 75078</td>
<td>CRB Healthcare Group, Inc.</td>
</tr>
<tr>
<td>Kremco Pharmacy</td>
<td>415 Westheimer Rd., Ste. 102-103, Houston, TX 77006 (O)</td>
<td>Kremco Pharmacy, LLC</td>
</tr>
<tr>
<td>Pharmacy Innovations</td>
<td>2936 W. 17th St., Erie, PA 16505</td>
<td>Richard Moon</td>
</tr>
<tr>
<td>MD Pharmacy</td>
<td>1601 Monte Vista, Ste. 130, Claremont, CA 91711</td>
<td>Golden State Holdings, LLC</td>
</tr>
<tr>
<td>Dakota Precision Rx, Inc.</td>
<td>705 E. Main Ave. Ste. 200, Bismarck, ND 58501</td>
<td>Dakota Precision Rx, Inc.</td>
</tr>
<tr>
<td>Choice Rx Pharmacy, Inc.</td>
<td>2030 NW Federal Hwy., Stuart, FL 34994</td>
<td>Choice Rx Acq, LLC</td>
</tr>
<tr>
<td>Geneva Pharmacy, LLC</td>
<td>20513 Nicholas Circle, Suite 3, Elkhorn, NE 68022</td>
<td>Tanner Anderson</td>
</tr>
<tr>
<td>Focus Rx Pharmacy Services, Inc.</td>
<td>2805 Veterans Memorial Hwy., Ronkonkoma, NY 11779</td>
<td>Focus Rx Pharmacy Services, Inc.</td>
</tr>
<tr>
<td>Unity Point at Home</td>
<td>1133 Aurora Ave., Urbandale, IA 50322</td>
<td>Iowa Health System</td>
</tr>
<tr>
<td>Rexford Pharmacy, Inc.</td>
<td>8610 S. Sepulveda Blvd. 106, Los Angeles, CA 90045</td>
<td>Rexford Pharmacy, Inc.</td>
</tr>
<tr>
<td>Empire Pharmacy</td>
<td>6509 Bergenline Ave., West New York, NJ 07093</td>
<td>Eduard Shindler</td>
</tr>
<tr>
<td>Lone Peak Rx, LLC</td>
<td>11724 S. State St., Ste. 102, Draper, UT 84020 (O)</td>
<td>Lone Peak Rx, LLC</td>
</tr>
<tr>
<td>Innovative Rx, LLC</td>
<td>12176 S. 100 E., Ste. 2, Draper, UT 84020</td>
<td>Innovative Rx, LLC</td>
</tr>
</tbody>
</table>

(O) = Ownership Change
5. (2) Non-Resident Pharmacy Permits (Out of State) – Schedule B
NON-RESIDENT PHARMACY PERMITS - Continued

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humana Pharmacy, Inc</td>
<td>12602 Toepperwein Rd., Suite 100, San Antonio, TX 78233</td>
<td>Humana Pharmacy, Inc</td>
</tr>
<tr>
<td>Humana Pharmacy, Inc.</td>
<td>100 S. Rainbow Blvd., Las Vegas, NV 89145</td>
<td>Humana Pharmacy, Inc</td>
</tr>
<tr>
<td>Conception Pharmacy</td>
<td>25301 Interstate 45 North, Suite B, The Woodlands, TX 77380</td>
<td>Conception Pharmacy, LLC</td>
</tr>
<tr>
<td>VRx by Mail, LLC</td>
<td>2256 South 3600 West, Suite A, Salt Lake City, UT 84119 (O)</td>
<td>Veridicus Holdings, LLC</td>
</tr>
<tr>
<td>VRx @ City Creek</td>
<td>50 East South Temple, Suite 145, Salt Lake City, UT 84111 (O)</td>
<td>Veridicus Holdings, LLC</td>
</tr>
<tr>
<td>Calhoun Compounding Pharmacy</td>
<td>990 Commercial Street SE, Salem, OR 97302</td>
<td>Calhoun Acquisition, LLC</td>
</tr>
<tr>
<td>Northern Pharmacy and Medical Equipment, Inc.</td>
<td>6701 Harford Rd., Baltimore, MD 21234</td>
<td>Northern Pharmacy and Medical Equipment, Inc.</td>
</tr>
<tr>
<td>Siena’s Pharmacy</td>
<td>1664 South Dixie Drive, L-106, St. George, UT 84770</td>
<td>Steven Kirkland</td>
</tr>
<tr>
<td>Curex Compounding Pharmacy, Inc.</td>
<td>5060 W. Sunset Blvd, Ste. C, Los Angeles, CA 90027</td>
<td>Curex Compounding Pharmacy, Inc.</td>
</tr>
<tr>
<td>Farmacia Libertad</td>
<td>9414 Parkfield Dr., Unit A, Austin, TX 78758</td>
<td>Andrew Coney, Jose Luis Davilla, Christopher Sprague</td>
</tr>
<tr>
<td>PETNET Solutions, Inc.</td>
<td>11175 Campus St., Suite C1037, Loma Linda, CA 92354</td>
<td>PETNET Solutions, Inc.</td>
</tr>
<tr>
<td>Essentia Health Specialty Pharmacy</td>
<td>3500 Tower Avenue, Suite B, Superior, WI 54880</td>
<td>The Duluth Clinic, LTD</td>
</tr>
<tr>
<td>Marley Drug, Inc.</td>
<td>5008 Peters Creek Parkway, Winston-Salem, NC 27127</td>
<td>Marley Drug, Inc.</td>
</tr>
<tr>
<td>Gulf Coast Scripts, LLC</td>
<td>761 Shamrock Blvd., Venice, FL 34293</td>
<td>Gulf Coast Scripts, LLC</td>
</tr>
<tr>
<td>One Source Pharmacy and Medical Supplies, LLC</td>
<td>15727 San Pedro Ave., San Antonio, TX 78232</td>
<td>San Antonio Pharmacy Holdings, LLC</td>
</tr>
<tr>
<td>Michaels Pharmacy</td>
<td>960 East Green St., Suite 152, Pasadena, CA 91106</td>
<td>Stephen Cobos</td>
</tr>
<tr>
<td>Essentia Health Prescription Service Center</td>
<td>3500 Tower Avenue, Suite C, Superior, WI 54880</td>
<td>The Duluth Clinic, LTD</td>
</tr>
<tr>
<td>Kings Daughters Pharmacy, LLC</td>
<td>1905 SW H.K. Dodgen Loop, Temple, TX 76502</td>
<td>Littleriver Healthcare Holdings, LLC</td>
</tr>
<tr>
<td>CRX Specialty Solutions</td>
<td>407 Bienville St., Natchitoches, LA 71457</td>
<td>Employer’s Health Network Holdings, LLC</td>
</tr>
<tr>
<td>Cottrill’s Pharmacy, Inc.</td>
<td>255 Main Street, Arcade, NY 14009</td>
<td>Cottrill’s Pharmacy, Inc.</td>
</tr>
<tr>
<td>Humana Pharmacy, Inc.</td>
<td>2001 E. Greenville St., Anderson, SC 29621</td>
<td>Humana Pharmacy, Inc</td>
</tr>
<tr>
<td>Humana Pharmacy, Inc.</td>
<td>101 Orchard Park Drive, Greenville, SC 29616</td>
<td>Humana Pharmacy, Inc</td>
</tr>
<tr>
<td>Big Bend Pharmacy, LLC</td>
<td>6045 E. Shelby Dr., Suite 1A, Memphis, TN 38141</td>
<td>Tennessee Healthcare Holdings, LLC</td>
</tr>
<tr>
<td>Delaney Pharmacy, LLC</td>
<td>2573 Richmond Rd., Ste. 300, Lexington, KY 40509</td>
<td>James Tudor</td>
</tr>
<tr>
<td>Whiteville Community Pharmacy, PLLC</td>
<td>2060 Highway 64, Suite G, Whiteville, TN 38075</td>
<td>Whiteville Community Holdings, LLC</td>
</tr>
</tbody>
</table>

(O) = Ownership Change
### 5. (2) Non-Resident Pharmacy Permits (Out of State) – Schedule B

**NON-RESIDENT PHARMACY PERMITS - Continued**

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedSavers Pharmacy</td>
<td>1800 W. 35th St., Austin, TX 78703</td>
<td>Chris Johnson</td>
</tr>
<tr>
<td>Allivet</td>
<td>480 W. 83rd St., Hialeah, FL 33014 (O)</td>
<td>Agropec Trading, LLC</td>
</tr>
<tr>
<td>Priority Care Pharmacy Solutions, LLC</td>
<td>211 10th Ave. North, Amory, MS 38821</td>
<td>Priority Healthcare Corp.</td>
</tr>
</tbody>
</table>

(O) = Ownership Change

### 5. (3) Resident Wholesaler Permits– Schedule C

**RESIDENT WHOLESALERS PERMITS**

<table>
<thead>
<tr>
<th>Wholesaler</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>4570 E. Cactus Rd., Phoenix, AZ 85032</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>1650 E. Tucson Marketplace Blvd., Tucson, AZ 85713</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>1444 S. Sossaman Rd., Mesa, AZ 85209</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>8400 West Shannon, Tolleson, AZ 85353</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>2450 E. Beardsley Rd., Phoenix, AZ 85080</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>595 S. Galleria Way , Chandler, AZ 85226</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>10000 E. McDowell Rd., Avondale, AZ 85392</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>17550 N. 79th Ave., Glendale, AZ 85308</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>6255 E. Grant Rd., Tucson, AZ 85712</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>15255 N. Hayden Rd., Scottsdale, AZ 85260</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>3901 W. Costco Dr., Scottsdale, AZ 85260</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>1445 W. Elliot Rd., Tempe, AZ 85284</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>4502 E. Oak St., Phoenix, AZ 85008</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>2887 S. Market St., Gilbert, AZ 85295</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>1646 W. Montebello Ave., Phoenix, AZ 85015</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>1415 N. Arizona Ave., Gilbert, AZ 85233</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>3911 Highway 69, Prescott, AZ 86301</td>
<td>Costco Wholesale Corporation</td>
</tr>
<tr>
<td>Costco Wholesale Corporation (Non-Prescription)</td>
<td>19001 N. 27th Ave., Phoenix, AZ 85027</td>
<td>Costco Wholesale Corporation</td>
</tr>
</tbody>
</table>
## 5. (3) Resident Wholesaler Permits– Schedule C
### RESIDENT WHOLESALERS PERMITS - Continued

<table>
<thead>
<tr>
<th>Wholesaler</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Choice Medical Supply, LLC (Full Service)</td>
<td>7375 W. Buckeye Rd., Phoenix, AZ 85043</td>
<td>First Choice Medical Supply Holding, Inc.</td>
</tr>
<tr>
<td>Gravity Pharmaceuticals, Inc. (Full Service)</td>
<td>4050 E. Cotton Center Blvd., Ste. 60, Phoenix, AZ 85040</td>
<td>Gravity Pharmaceuticals, Inc.</td>
</tr>
</tbody>
</table>

## 5. (4) Non-Resident Wholesaler Permits – (Out of State) Schedule D
### NON-RESIDENT MANUFACTURER PERMITS

<table>
<thead>
<tr>
<th>Wholesaler</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reckitt Benckiser, LLC (Non-Prescription)</td>
<td>2001 Premier Parkway South, St. Peters, MO 63303</td>
<td>Reckitt Benckiser, LLC</td>
</tr>
<tr>
<td>Landmark Supply, Inc. (Full Service)</td>
<td>199 Main Street, 2nd Floor, Kearnsburg, NJ 07734</td>
<td>Landmark Supply, Inc.</td>
</tr>
<tr>
<td>Anutra Medical (Full Service)</td>
<td>1000 Perimeter Park Dr., Suite E, Morrisville, NC 27560</td>
<td>Dan Davidian</td>
</tr>
<tr>
<td>Mas Management Group, Inc.(Full Service)</td>
<td>28446 Constellation Rd., Valencia, CA 91355</td>
<td>Mas Management Group, Inc.</td>
</tr>
<tr>
<td>Hercules Pharmaceuticals, Inc. (Full Service)</td>
<td>27 Seaview Blvd., Port Washington, NY 11050</td>
<td>Hercules Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Home Aide Diagnostics, Inc. (Non-Prescription)</td>
<td>1072 S. Powerline Rd., Deerfield Beach, FL 33442</td>
<td>Home Aide Diagnostics, Inc.</td>
</tr>
<tr>
<td>Reliable Pharmaceutical Returns, LLC (Full Service)</td>
<td>1443 Donelson Pike, Nashville, TN 37217</td>
<td>Reliable Pharmaceutical Returns, LLC</td>
</tr>
<tr>
<td>Lifeline Pharmaceuticals, LLC (Full Service)</td>
<td>5800 Gulf Tech Dr., Ocean Springs, MI 39564</td>
<td>Lifeline Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>West-Ward Pharmaceuticals (Full Service)</td>
<td>2130 Rohr Rd., Lockbourne, OH 43137</td>
<td>West-Ward Pharmaceuticals</td>
</tr>
<tr>
<td>Xspire Pharma (Full Service)</td>
<td>121 Marketridge Dr., Suite B, Ridgeland, MS 39157</td>
<td>Ford Mundy</td>
</tr>
<tr>
<td>Optime Care, Inc. (Full Service)</td>
<td>4064 Wedgeay Ct., Earth City, MO 63045</td>
<td>Optime Care, Inc.</td>
</tr>
<tr>
<td>Amazon.com.indc. LLC (Full Service)</td>
<td>4255 Anson Blvd., Whitestown, IN 46075</td>
<td>Amazon.com.kydc, LLC</td>
</tr>
<tr>
<td>Amazon.com.indc. LLC (Full Service)</td>
<td>715 Airtech Parkway, Plainfield, IN 46168</td>
<td>Amazon.com.kydc, LLC</td>
</tr>
<tr>
<td>Lone Star Pharmaceuticals, Inc. (Full Service)</td>
<td>11951 Hilltop Rd., Suite 18, Argyle, TX 76226</td>
<td>Randall McKitrick</td>
</tr>
<tr>
<td>NDC Distributors, LLC (Full Service)</td>
<td>1825 65th St., Suite 300, Brooklyn, NY 11204</td>
<td>NDC Distributors, LLC</td>
</tr>
<tr>
<td>Hikma Americas, Inc. (Virtual)</td>
<td>5865 Ridgeway Center Parkway, Suite 300, Office 352, Shelby, TN 38120</td>
<td>Hikma Americas, Inc.</td>
</tr>
<tr>
<td>MedArbor, LLC (Full Service)</td>
<td>150 Monument Rd., Suite 601E, Bala Cynwyd, PA 19004</td>
<td>Miroslav Kesic</td>
</tr>
<tr>
<td>Mallinckrodt Nuclear Medicine, LLC (Full Service)</td>
<td>2703 Wagner Place, Maryland Heights, MO 63043</td>
<td>Mallinckrodt Nuclear Medicine, LLC</td>
</tr>
</tbody>
</table>
5. (5) Resident Manufacturer Permits – Schedule E

**RESIDENT MANUFACTURER PERMITS**

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Westmed, Inc</td>
<td>5580 S. Nogales Hwy., Tucson, AZ 85706</td>
<td>Westmed Holding, Inc.</td>
</tr>
<tr>
<td>Dexcom, Inc.</td>
<td>232 S. Dobson Rd., Mesa, AZ 85202</td>
<td>Dexcom, Inc.</td>
</tr>
</tbody>
</table>

5. (6) Non-Resident Manufacturer Permits – (Out of State) Schedule F

**NON-RESIDENT MANUFACTURER PERMITS**

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutanea Life Sciences, Inc. (Virtual)</td>
<td>1500 Liberty Ridge Dr., Wayne, PA 19087</td>
<td>Maruho Company, Ltd.</td>
</tr>
<tr>
<td>Radius Health, Inc. (Virtual)</td>
<td>950 Winter St., Waltham, MA 02451</td>
<td>Radius Health, Inc.</td>
</tr>
<tr>
<td>Bayer Healthcare Pharmaceuticals, Inc.</td>
<td>100 Bayer Blvd., Whippany, NJ 07981</td>
<td>Bayer Healthcare, LLC</td>
</tr>
<tr>
<td>Acelle Pharmaceuticals, LLC (Virtual)</td>
<td>11675 Great Oaks Way, Suite 144, Alpharetta, GA 30022</td>
<td>Acelle Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>Acura Pharmaceuticals, Inc. (Virtual)</td>
<td>616 N. Court, Suite 120, Palantine, IL 60067</td>
<td>Acura Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Alembic Pharmaceuticals, Inc. (Virtual)</td>
<td>750 Route 202, Suite 410, Bridgewater, NJ 08807</td>
<td>Alembic Global Holding SA</td>
</tr>
<tr>
<td>Amneal Biosciences, LLC (Virtual)</td>
<td>400 Crossing Blvd., Third Floor, Bridgewater, NJ 08807</td>
<td>Amneal Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>Aratana Therapeutics, Inc. (Virtual)</td>
<td>1400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211</td>
<td>Franklin Resources, Inc., and Prudential Financial, Inc.</td>
</tr>
<tr>
<td>Avion Pharmaceuticals, LLC (Virtual)</td>
<td>11675 Great Oaks Way, Suite 120, Alpharetta, GA 30022</td>
<td>Avion Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>Micro Labs USA, Inc. (Virtual)</td>
<td>104 Carneige Center, Suite 216, Princeton, NJ 08540</td>
<td>Micro Labs Limited</td>
</tr>
<tr>
<td>Nivagen Pharmaceuticals, Inc. (Virtual)</td>
<td>3100 Fite Circle, Suite 208, Sacramento, CA 95827</td>
<td>Nivagen Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Cipla USA, Inc. (Virtual)</td>
<td>9100 S. Dadeland Blvd., Suite 1500, Miami, FL 33156</td>
<td>InvaGen Pharmaceuticals, Inc., USA</td>
</tr>
<tr>
<td>Sentiss Pharmaceuticals, LLC (Virtual)</td>
<td>107 Avenida de la Estrella, San Clemente, CA 92672</td>
<td>Sentiss AG</td>
</tr>
<tr>
<td>Avadel Pharmaceuticals</td>
<td>16640 Chesterfield Grove Rd, Suite 200, Chesterfield, MO 63005</td>
<td>Avadel Pharmaceuticals (USA), Inc.</td>
</tr>
<tr>
<td>Sergeant’s Pet Care Products, Inc. (Virtual)</td>
<td>10077 S. 134th St., Omaha, NE 68138</td>
<td>Perrigo Company</td>
</tr>
<tr>
<td>Sigma-Tau Pharmaceuticals, Inc. (Virtual)</td>
<td>9841 Washingtonian Blvd., Suite 500, Gaithersburg, MD 20878</td>
<td>Essetfin S.p.A</td>
</tr>
<tr>
<td>Bio-Pharm, LLC (Virtual)</td>
<td>409 W. Hallandale Beach Blvd., Suite 127, Hallandale, FL 33009</td>
<td>Bio-Pharm, Inc. Echo Bay Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>Zoetis US, LLC (Virtual)</td>
<td>10 Sylvan Way, Parsippany, NJ 07054</td>
<td>Zoetis, Inc.</td>
</tr>
<tr>
<td>Canton Laboratories, LLC (Virtual)</td>
<td>1015 Nine North Dr., Alpharetta, GA 30004</td>
<td>Canton Laboratories, LLC</td>
</tr>
<tr>
<td>Edenbridge Pharmaceuticals, LLC</td>
<td>300 Interpace Parkway, Parsippany, NJ 07054</td>
<td>Wood Creek Venture Fund, LLC</td>
</tr>
</tbody>
</table>
### NON-RESIDENT MANUFACTURER PERMITS - Continued

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>QOL Medical, LLC (Virtual)</td>
<td>3405 Ocean Drive, Vero Beach, FL 32963</td>
<td>QOL Medical, LLC</td>
</tr>
<tr>
<td>Alvix Laboratories, LLC</td>
<td>6601 Sunplex Drive, Ocean Springs, MS 39564</td>
<td>Alvix Laboratories, LLC</td>
</tr>
<tr>
<td>Iroko Pharmaceuticals, LLC (Virtual)</td>
<td>One Kew Place, 150 Rouse Blvd., Philadelphia, PA 19112</td>
<td>Iroko Holdings, LLC</td>
</tr>
<tr>
<td>Jurox , Inc (Virtual)</td>
<td>4520 Main Street, Kansas City, MO 64111</td>
<td>Jurox Pty. Limited</td>
</tr>
<tr>
<td>Laser Pharmaceuticals, LLC (Virtual)</td>
<td>6017 Ponders Ct, Greenville, SC 29615</td>
<td>Canton Laboratories, LLC</td>
</tr>
<tr>
<td>Laydan Labs, LLC (Virtual)</td>
<td>5400 Laurel Springs Parkway, Suite 504, Suwanee, GA 30024</td>
<td>Legacy United, LLC</td>
</tr>
<tr>
<td>TruPharma, LLC (Virtual)</td>
<td>4100 Kennedy Boulevard, Suite 220, Tampa, FL 33609</td>
<td>TruPharma Holding, LP</td>
</tr>
<tr>
<td>WellSpring Pharmaceuticals Corporation (Virtual)</td>
<td>5911 N. Honroe Ave., Suite 211, Sarasota, FL 34243</td>
<td>WSP Intermediate Corp</td>
</tr>
<tr>
<td>Alliqua Biomedical Inc.</td>
<td>11495 Valley View Rd., Eden Prairie, MN 55344</td>
<td>Alliqua Biomedical Inc.</td>
</tr>
<tr>
<td>Nephon Sterile Compounding Center, LLC (Outsourcing)</td>
<td>4500 12th St. Extension, West Columbia, SC 29172</td>
<td>Nephon Sterile Compounding Center, LLC</td>
</tr>
<tr>
<td>Liebel-Flarshiem, LLC</td>
<td>1034 S. Brentwood Blvd., Suite 800, Richmond Heights, MO 63117 (O)</td>
<td>Guerbert, LLC</td>
</tr>
<tr>
<td>Somerset Therapeutics, LLC (Virtual)</td>
<td>475 Bernardsville Rd., Mendham, NJ 07945</td>
<td>Somerset Therapeutics, LLC</td>
</tr>
<tr>
<td>Avella of Houston (Outsourcing)</td>
<td>9265 Kirby Dr., Houston, TX 77054</td>
<td>Advance Pharma, Inc.</td>
</tr>
<tr>
<td>Athenex Pharmaceutical Division, LLC (Virtual)</td>
<td>20 N. Martinale Rd., Suite 180-1023, Schaumburg, IL 60173</td>
<td>Athenex, Inc</td>
</tr>
<tr>
<td>Bionpharma, Inc. (Virtual)</td>
<td>600 Alexander Rd., Suite 2-4B, Princeton, NJ 08540</td>
<td>Pharmascience Inc., LOF, Bion, Partnership, LP</td>
</tr>
<tr>
<td>Vensun Pharmaceuticals, Inc. (Virtual)</td>
<td>790 Township Line Rd., Suite 250, Yardley, PA 19067</td>
<td>Vensun Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Dukal Corporation (Virtual)</td>
<td>2 Fleetwood Court, Ronkonkoma, NY 11779</td>
<td>Dukal Corporation</td>
</tr>
<tr>
<td>Photocure, Inc. (Virtual)</td>
<td>104 Carnegie Center, Suite 303, Princeton, NJ 08540</td>
<td>Photocure, ASA</td>
</tr>
<tr>
<td>iVaoes, LLC (Virtual)</td>
<td>4300 SW 73rd Ave., Suite 109, Miami, FL 33155</td>
<td>iVaoes, LLC</td>
</tr>
<tr>
<td>Sigma-Tau Healthscience USA, Inc. (Virtual- Nutraceuticals)</td>
<td>9841 Washingtonian Blvd, Suite 502, Gaithersburg, MD 20878</td>
<td>Sigma-Tau Farmaceutiche Riunite, S.p.A.</td>
</tr>
<tr>
<td>Jacksonville Pharmaceuticals, Inc. (Virtual)</td>
<td>818 AIA N #205, Ponte Vedra, FL 32082</td>
<td>Jacksonville Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Espero Pharmaceuticals, Inc. (Virtual)</td>
<td>818 AIA N #205, Ponte Vedra, FL 32082</td>
<td>Espero Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Mannkind Corp. (Virtual)</td>
<td>1 Casper St., Danbury, CT 06810</td>
<td>Alfred E. Mann Living Trust</td>
</tr>
<tr>
<td>Becton, Dickinson and Company</td>
<td>1852 10th Ave., Columbus, NE 68601</td>
<td>Becton, Dickinson and Company</td>
</tr>
<tr>
<td>Bayer HealthCare LLC (Virtual)</td>
<td>100 Bayer Blvd., Whippany, NJ 07981</td>
<td>Bayer Corp.</td>
</tr>
</tbody>
</table>

(O) = Ownership Change
5. (6) Non-Resident Manufacturer Permits – (Out of State) Schedule F

NON-RESIDENT MANUFACTURER PERMITS - Continued

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Isotopes, Inc.</td>
<td>4137 Commerce Circle, Idaho Falls, ID 83401</td>
<td>International Isotopes, Inc.</td>
</tr>
<tr>
<td>Lexicon Pharmaceuticals, Inc.</td>
<td>8800 Technology Forest Place, The Woodlands, TX 77381</td>
<td>Lexicon Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Zynex Medical, Inc.</td>
<td>10000 Park Meadows Dr., Lone Tree, CO 80124</td>
<td>Zynex Medical, Inc.</td>
</tr>
<tr>
<td>Flexion Therapeutics, Inc.</td>
<td>10 Mall Road, Suite 301, Burlington, MA 01803</td>
<td>Flexion Therapeutics, Inc.</td>
</tr>
<tr>
<td>Abraxis Bioscience, LLC</td>
<td>86 Morris Avenue, Summit, NJ 07901</td>
<td>Abraxis Bioscience, Inc.</td>
</tr>
</tbody>
</table>

Mr. Blaire asked that the following applications be tabled because the addresses are the same and or the managers were the same:

1. Cronus Pharma, LLC
2. Casper Pharma, LLC
3. Strides Pharma, Inc.
4. Lucid Pharma, LLC
5. Citron Pharma, PPC

5. (7) – New Pharmacists – Schedule G
The Board approved the 74 New Pharmacist Licenses listed on the attachments.

5. (8) – New Interns – Schedule H
The Board approved the 16 New Intern Licenses listed on the attachments.

5. (9) – New Pharmacy Technicians – Schedule I
The Board approved the 310 New Pharmacy Technicians listed on the attachments.

5. (10) – Pharmacy Technician Trainee Requests for Approval to Reapply for Licensure – Schedule J
The Board approved the 164 Pharmacy Technician Trainee Reapply requests listed on the attachments. The Pharmacy Technician Trainees are approved for one additional two year period.

5. (11) – Approval of Colleges and Schools of Pharmacy – Schedule K
The Board unanimously approved the ACPE accredited programs of Colleges and Schools of Pharmacy.

5. (12) – Approval of Licensing Exams – Schedule L
The Board unanimously approved the following exams for Licensure:
   1. NAPLEX
   2. MPJE
   3. FPGEEC
   4. PTCB and ExCPT

5. (13) – Approval of Designee Duties – Schedule M
The Board unanimously approved the Designee Duties as listed in the Board attachments.
AGENDA ITEM 6– Resident Pharmacy Permits – Schedule N

1. Walgreens Mail Service – Ownership Change

Vice President Van Hassel stated that Mr. Kennedy was recused due to a conflict of interest. **On motion by Ms. Locnikar and seconded by Dr. Dang**, the Board unanimously agreed to approve the ownership change application for Walgreens Mail Service.

2. American Premier Pharmacy

President Kennedy stated that a representative from American Premier Pharmacy was present to answer questions from Board Members.

The following individual was present:
1. Fraser Henderson – Owner and Pharmacist in Charge

President Kennedy asked the applicant to describe their business model. Mr. Henderson stated that he plans on opening a pharmacy that specializes in home infusions. Mr. Henderson stated that he has worked in home infusion pharmacies. Mr. Henderson stated that he would be servicing home health and hospice patients.

Mr. Blaire asked Mr. Henderson if he would be preparing sterile products. Mr. Henderson replied yes. Mr. Blaire asked Mr. Henderson if he would be preparing any hazardous products. Mr. Henderson replied no.

Mr. Blaire stated that he had concerns about a sink not be located in the preparation area. Mr. Henderson stated that he can add a sink. Mr. Henderson indicated that there is a sink located outside of the breakroom.

Mr. Van Hassel asked if he planned on installing a laminar flow bench. Mr. Henderson stated that he is waiting for Board approval prior to buying the hood.

Dr. Dang asked if they would have a narcotic safe. Mr. Henderson replied that they would have a safe.

Mr. Van Hassel asked if they would dispense other medications. Mr. Henderson stated that they would dispense other medications for the hospice patients.

Mr. Van Hassel asked where they would compound oral medications. Mr. Henderson replied that they would be compounded on the back counter.

**On motion by Dr. Dang and seconded by Mr. Blaire**, the Board unanimously agreed to approve the application for American Premier Pharmacy.

3. Raintree Apothecary

President Kennedy stated that representatives from Raintree Apothecary were present to answer questions from Board Members.
The following individuals were present:
1. Erin Butler – Owner and Pharmacist in Charge
2. Bill Olstander - Owner

President Kennedy asked the applicants to describe their business model. Ms. Butler stated that the pharmacy would be a retail pharmacy and they would do non-sterile compounding.

Mr. Blaire asked about the floorplan and the counter space. Ms. Butler stated that the counter would extend the length of the wall.

Mr. Blaire asked about the preparation of hazardous products. Ms. Butler stated that they would have a negative pressure room.

Mr. Blaire asked about going through the breakroom to prepare hazardous products and possible contamination issues. Ms. Butler stated that they are looking at putting in a door so that they would not be going through the breakroom.

Mr. Blaire asked about security measures because two of the owners are not pharmacists. Ms. Butler indicated that they are aware that they cannot be in the pharmacy if a pharmacist is not present.

On motion by Mr. Blaire and seconded by Ms. Snair, the Board unanimously agreed to approve the application for Raintree Apothecary.

4. Hope Pharmacy

President Kennedy stated that representatives from Hope Pharmacy were present to answer questions from Board Members.

The following individuals were present:
1. Hilda Agajanian - Owner
2. Dr. Richy Agajanian – Owner (via telephone)
3. Roger Morris – Legal Counsel for Hope Pharmacy

President Kennedy asked the applicants to describe their business model. Mr. Morris stated that the pharmacy will be a retail pharmacy serving oncology patients. Mr. Morris stated that they would be compounding sterile and non-sterile products.

Mr. Kennedy asked if they have ever owned a pharmacy. Ms. Agajanian stated that they own a dispensary in California.

Mr. Morris stated that the floor plan is a rough draft floor plan and will be redesigned once they hire a pharmacist. Mr. Morris stated that the floor plans will meet 795 and 797 rules.

Mr. Blaire asked if there would be any transferring of products between the pharmacies. Ms. Agajanian replied no.

Ms. Snair asked if all the patients would be in Arizona. Ms. Agajanian replied yes.
Mr. McAllister asked Mr. Morris to address the issues with the physician owner. Dr. Agajanian stated that he would not be authorizing any prescriptions that would be filled at the pharmacy.

Mr. Van Hassel asked Dr. Agajanian what area of medicine he practices. Dr. Agajanian stated that he has not practiced for 5 years and does not have any patient contact. Dr. Agajanian stated that he has a California license.

Mr. Van Hassel indicated that he would like to see the floor plan prior to inspection.

Mr. Blaire reminded that the applicants that their office would also need to be USP 800 compliant.

On motion by Mr. McAllister and seconded by Mr. Minkus, the Board unanimously agreed to approve the application for Hope Pharmacy.

RESIDENT PHARMACY PERMITS

The Board unanimously approved the resident pharmacy permits below pending final inspection.

RESIDENT PHARMACY PERMITS – Schedule N

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walgreens Mail Service</td>
<td>8350 S. River Parkway, Tempe, AZ 85284 (O)</td>
<td>Walgreens Mail Service, LLC</td>
</tr>
<tr>
<td>American Premier Pharmacy</td>
<td>4745 N. 7th St., Suite 245, Phoenix, AZ 85014</td>
<td>Fraser Henderson</td>
</tr>
<tr>
<td>Raintree Apothecary</td>
<td>9260 E. Raintree Dr., Ste. 150, Scottsdale, AZ 85260</td>
<td>Raintree Apothecary, LLC</td>
</tr>
<tr>
<td>Hope Pharmacy</td>
<td>1701 W. St. Mary Rd., Suite 100-B Tucson, AZ 85745</td>
<td>Richy Agajanian, MD</td>
</tr>
</tbody>
</table>

(O) = Ownership Change

AGENDA ITEM 7– Non-Resident Pharmacy Permits – Schedule O

1. John’s Pharmacy

President Kennedy stated that a representative from John’s Pharmacy was present telephonically to answer questions from Board Members.

The following individual was present telephonically:
1. Joseph Catalano – Pharmacist in Charge

President Kennedy opened the discussion by stating that John’s Pharmacy has applied for a non-resident pharmacy permit but have relinquished their sterile compounding license in Florida.

Mr. Catalano stated that John Ward who previously owned the pharmacy has retired. Mr. Catalano stated that the pharmacy was purchased from Mr. Ward as a stock purchase. Mr. Catalano stated that they purchased the license and the reprimands that went with the license.
Mr. Catalano stated that they have a sterile facility but the owner and previous pharmacist did not have the knowledge to operate a sterile facility. Mr. Catalano stated that they have a sterile facility but he does not have any materials to make sterile products.

Mr. Blaire asked when the Florida Board last inspected the facility. Mr. Catalano stated that it was in September but he does not have the exact date. Mr. Catalano stated that he can e-mail or fax a copy to the Board Office.

Mr. Blaire asked if they had a license in Arizona previously. Mr. Catalano stated that the old owner had a license but had no customers so he did not keep the license.

Ms. Snair asked Mr. Catalano if he worked with Mr. Ward. Mr. Catalano stated that he did not work with Mr. Ward and no one in the current management group worked with Mr. Ward.

Mr. Van Hassel asked Mr. Catalano if they plan to return to sterile compounding. Mr. Catalano stated that the new owners would like to pursue sterile compounding but it would probably be only in the state of Florida.

Mr. Kennedy asked if the pharmacy would sign a statement that they would not ship sterile compounds into Arizona. Mr. Catalano stated that he would reach out to his legal counsel and upon his advice would send the appropriate paperwork.

On motion by Mr. Van Hassel and seconded by Mr. Skvarla, the Board unanimously agreed to table their decision until they receive a copy of the pharmacy inspection and the statement indicating that they would not ship sterile products into Arizona.

AGENDA ITEM 8– Resident Manufacturer – Schedule P

1. Atlas Pharmaceuticals

President Kennedy stated that representatives from Atlas Pharmaceuticals were present to answer questions from Board Members.

The following individuals were present;
1. Nancy Costlow – Pharmacist and Manager
2. Rob Eaton - Owner

President Kennedy asked the applicants to describe their business model. Ms. Costlow stated that they are applying for a resident manufacturer permit for a 503B facility. Ms. Costlow stated that they would compound medications for office use and human sterile compounding.

Mr. Blaire asked if any of the customers are humans. Ms. Costlow replied no.

Mr. Blaire asked if they have performed any testing of the products.

Prior to Ms. Costlow answering the question, Mr. Eaton asked that Mr. Blaire recuse himself because he was a competitor.

Mr. Blaire recused himself.
Mr. Van Hassel asked about the compounding area. Ms. Costlow stated that they are remodeling an existing building.

Mr. Van Hassel asked if they would be primarily compounding veterinary medications. Mr. Eaton stated that they would need to compound some human drugs.

Mr. Skvarla asked what human products they were planning on compounding. Ms. Costlow stated that they plan to compound vancomycin.

Mr. Skvarla asked what products they are currently compounding. Ms. Costlow stated that they compound veterinary compounds.

Mr. Van Hassel asked when they plan to open. Mr. Eaton stated that they plan to open in 4 to 6 weeks. Ms. Costlow stated that they have to validate the facility.

Mr. McAllister asked about a 503 (B) inspection by the FDA. Mr. Eaton stated that they have to be operating in order for an inspection to occur.

Mr. Van Hassel asked about the FDA inspection at the pharmacy. Mr. Eaton stated that the inspection was for Roadrunner Pharmacy and not this facility.

Mr. Van Hassel placed a motion on the floor to table the application until an FDA inspection is completed. The motion was seconded by Mr. Skvarla. The motion was withdrawn.

Mr. Eaton stated that they must be operating and the FDA would not inspect the facility for several months.

On motion by Dr. Dang and seconded by Mr. Skvarla, the Board unanimously agreed to meet in Executive Session.

The Board returned to Regular Session.

On motion by Mr. Van Hassel and seconded by Mr. McAllister, the Board unanimously agreed to grant the license pending an equipment check by the Board and a follow inspection after up and running. The FDA report should also be sent to the Board

The Board unanimously approved the resident manufacturer permit below pending final inspection.

**RESIDENT MANUFACTURER PERMIT – Schedule P**

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
</table>
AGENDA ITEM 9– Non-Resident Manufacturer – Schedule Q

1. Edge Pharmacy Services, LLC

President Kennedy stated that a representative from Edge Pharmacy Services, LLC was present telephonically to answer questions from Board Members.

The following individual was present telephonically:
1. William Chatoff -Owner

President Kennedy asked the applicant to describe their business model. Mr. Chatoff stated that they are applying for a non-resident manufacturer. Mr. Chatoff stated that they are a 503 (B) outsourcing facility that supplies medications to hospitals and clinics. Mr. Chatoff stated that they prepare low, medium, and high risk products.

Mr. Kennedy asked Mr. Chatoff to discuss their FDA Warning Letter. Mr. Chatoff stated that in August of 2014 they were inspected by the FDA. Mr. Chatoff stated that they responded to the 483 and received a warning letter. Mr. Chatoff stated that they hired a consultant to help with the FDA letter. Mr. Chatoff stated that they responded to each and every observation and have received correspondence from the FDA.

Mr. Blaire asked if they had an FDA labeler code. Mr. Chatoff stated that a 503 (B) facility is not issued a labeler code. Mr. Chatoff stated that the numbers that they assigned the products were self-generated and they attached them to the product. Mr. Chatoff stated that the numbers have no correlation with a new drug application. Mr. Chatoff stated that it was an internal way of identifying the product.

Mr. Blaire asked if they have been inspected by the Vermont Board of Pharmacy. Mr. Chatoff stated that they were inspected and he can send a copy of the inspection. Mr. Chatoff stated that the FDA just left and the warning letter will be closed out.

Mr. Blaire asked if they prepared any products in combination with Fentanyl. Mr. Chatoff stated that they have not prepared any narcotics.

Mr. Blaire asked Mr. Chatoff to send an up-to-date product list.

Mr. Van Hassel asked Mr. Chatoff if their facility is USP 800 compliant. Mr. Chatoff stated that they are building a new clean room which is USP compliant and they have 1,000 square feet that is USP 800 compliant.

On motion by Mr. Blaire and seconded by Mr. Van Hassel, the Board unanimously agreed to approve the non-resident manufacturer permit for Edge Pharmacy Services, LLC pending receipt of the updated product list.
The Board unanimously approved the non-resident manufacturer permit below.

NON-RESIDENT MANUFACTURER PERMIT – Schedule Q

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edge Pharmaceuticals, LLC</td>
<td>586 Hercules Dr., Ste. 30, Colchester, VT 05446</td>
<td>William Chatoff</td>
</tr>
</tbody>
</table>

AGENDA ITEM 10– Non-Resident Wholesaler – ScheduleR

1. Midwest Veterinary Supply, Inc.

President Kennedy stated that a representative from Midwest Veterinary Supply, Inc. was present telephonically to answer questions from Board Members.

The following individual was present telephonically:
1. Guy Flickinger – CEO

President Kennedy acknowledged that Midwest Veterinary Supply, Inc. was applying for a non-resident wholesaler permit. Mr. Kennedy asked Mr. Flickinger to address the various board orders.

Mr. Flickinger stated that the order in Minnesota resulted from then taking orders from customers and sending them to a pharmacy that sold the medications to veterinarians and these were considered wholesale transactions.

Mr. Kennedy asked if they have shipped to Arizona. Mr. Flickinger stated that their other warehouses that are licensed in Arizona have shipped to Arizona.

Mr. Blair asked who handles compliance issues. Mr. Flickinger stated that Richard Sarrazin the manager handles compliance issues.

Matt Rischette, handles licensing issues for the firm.

Mr. Blair asked how many facilities they own. Mr. Rischette stated that they have 7 facilities. Mr. Rischette stated that 45 days prior to expiration of a license they are notified. Mr. Rischette stated that all licenses are electronically scanned.

Mr. Blaire asked Mr. Rischette how long he has been with the company. Mr. Rischette stated that he has been with the company for 1½ years.

Mr. Flickinger stated that in Ohio they shipped to a veterinarian that was not registered. Mr. Flickinger stated that their computer system now verifies all licenses.

Mr. Flickinger stated that in Maryland they shipped to Maryland from their Pennsylvania facility that was not licensed in Maryland. Mr. Flickinger stated that the computer will let them know if they are licensed to ship into that state.
On motion by Mr. Blaire and seconded by Dr. Dang, the Board approved the non-resident wholesaler permit for Midwest Veterinary Supply, Inc. There was one nay vote by Mr. Minkus.

The Board approved the non-resident wholesaler permit below.

**NON-RESIDENT WHOLESALER PERMIT – Schedule R**

<table>
<thead>
<tr>
<th>Wholesaler</th>
<th>Location</th>
<th>Owner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midwest Veterinary Supply, Inc.</td>
<td>2835 Coleman St., North Las Vegas, NV 89032</td>
<td>Midwest Veterinary Supply, Inc.</td>
</tr>
</tbody>
</table>

**AGENDA ITEM 11– Special Requests – Schedule S**

#1 Colin Gerber

Colin Gerber appeared on his own behalf to request to terminate the suspension per Board Order 16-0008-PHR. Sigberto Celaya, legal counsel, for Mr. Gerber was also present.

President Kennedy asked Mr. Gerber to address his request. Mr. Gerber stated that he is requesting that the Board terminate his suspension. Mr. Gerber stated that he attends three AA meetings a week, is on Step 10 with his sponsor, and has resided in a sober living facility.

Mr. Gerber stated that he has been subjected to numerous screens and has had all negative results. Mr. Gerber stated that he volunteers and coordinates fund raising events. Mr. Gerber stated that he is a trainer at a fitness center.

Mr. Gerber expressed remorse for his actions.

Mr. McAllister stated that the agreement states at the end of February he could appear. Mr. Gerber replied that he is requesting the lifting of his probation, so that he may start his rotations, but he cannot start his rotations until January of next year.

Mr. Van Hassel asked how many years remain on his PAPA contract. Ms. Marcum (PAPA administrator) stated that there are 4 years left on his contract. Ms. Marcum stated that he is making efforts. Ms. Marcum stated that his urine screens have been negative and he is working a good program.

Mr. Skvarla asked Mr. Gerber where he is today in his life. Mr. Gerber stated that he is accepting sobriety. Mr. Gerber stated that at social settings he does not drink. Mr. Gerber stated that he has a passion for pharmacy. Mr. Gerber stated that he has learned about addiction and addiction is an issue in the pharmacy world.
Ms. Snair asked about his sponsor. Mr. Gerber stated that his sponsor is in Boston and he has seen him twice in the last 6 months. Mr. Gerber stated that his sponsor has 12 years of sobriety. Mr. Gerber stated that he has maintained his sobriety since May 2016.

Mr. Van Hassel asked Mr. Gerber to convince him that he is ready to go back into pharmacy. Mr. Gerber stated that he wants to reach the next milestone and has accepted his addiction.

Mr. Celaya stated that Mr. Gerber is more responsive in the process. Mr. Celaya stated that often Mr. Gerber would not return their e-mails or phone calls.

Ms. Snair asked Mr. Gerber if he feels that pharmacy is the profession for him. Mr. Gerber stated that it has crossed his mind but it is something he wants for himself.

Mr. Gerber indicated that would like to get a job in the MTM center again. Mr. Gerber stated that he feels that he is out of the loop because the pharmacy environment is always changing.

**On motion by Mr. McAllister and seconded by Ms. Locnikar**, the Board unanimously agreed to remove the suspension and impose probation for the remainder of the PAPA contract. Mr. Gerber must maintain his PAPA contract and notify each employer and preceptor about his consent agreement until he graduates. A roll call vote was taken (Mr. Blair – aye, Dr. Dang – aye, Mr. Minkus – aye, Mr. Skvarla – aye, Mr. Van Hassel – nay, Mr. McAllister- aye, Ms. Snair – aye) Ms. Locnikar left at 2:45.

**AGENDA ITEM 12– License Applications Requiring Board Review – Schedule T**

#1 Brianna Herrick

Brianna Herrick appeared on her own behalf to request to proceed with Pharmacy Technician licensure.

President Kennedy opened the discussion by asking Ms. Herrick why she was appearing in front of the Board.

Ms. Herrick stated that she is applying for a pharmacy technician license and was requested to appear due to her background. Ms. Herrick stated that she was certified in Minnesota and is nationally certified as a technician. Ms. Herrick stated that she has worked preparing sterile compounds. Ms. Herrick stated that she is married and she has moved to Arizona because her husband is attending ASU.

Ms. Herrick stated that in 2010 she was charged with 2 DUIs. Ms. Herrick stated that she had completed her probation. Ms. Herrick stated that she had a probation officer that took her under her wing and helped her with the alcohol issues.

Mr. Kennedy asked Ms. Herrick if she currently drinks alcohol. Ms. Herrick replied no.

**On motion by Ms. Snair and seconded by Mr. Blaire**, the Board unanimously agreed to approve Ms. Herrick’s pharmacy technician application.
#2 Stephanie McFarland

Mr. Kennedy was recused due to a conflict of interest.

Stephanie McFarland appeared on her own behalf to request to proceed with Pharmacy Technician licensure.

Vice President Van Hassel opened the discussion by asking Ms. McFarland why she was appearing in front of the Board.

Ms. McFarland stated that she is applying for a pharmacy technician license and had been asked to appear because in 2011 she was charged with an undesignated felony that was reduced to a misdemeanor in 2014. Ms. McFarland stated that she previously held a training license.

Ms. Snair asked Ms. McFarland to explain her offense. Ms. McFarland stated that she was charged with a DUI.

Ms. Galvin asked Ms. McFarland about her endangerment charge. Ms. McFarland stated that she had her two children in the car with her.

On motion by Mr. McAllister and seconded by Ms. Locnikar, the Board unanimously agreed to approve Ms. McFarland’s pharmacy technician application.

#3 Samantha Kurowski

Mr. Kennedy was recused due to a conflict of interest.

Samantha Kurowski appeared on her own behalf to request to proceed with Pharmacy Technician Trainee licensure.

Vice President Van Hassel opened the discussion by asking Ms. Kurowski why she was appearing in front of the Board.

Ms. Kurowski stated that she was applying for a pharmacy technician trainee license. Ms. Kurowski stated that she is working at Walgreens as a shift lead.

Ms. Kurowski stated that she was charged with a DUI in 2010 that was a misdemeanor.

Ms. Snair asked about the assault charge. Ms. Kurowski stated that she had an argument with ex-boyfriend and they were both charged with domestic violence. Ms. Kurowski stated that her charges were dismissed in 2016.

On motion by Mr. McAllister and seconded by Dr. Dang, the Board unanimously agreed to approve Ms. Kurowski’s pharmacy technician trainee application.

#4 Sara Schwarz

Mr. Kennedy was recused due to a conflict of interest.

Ms. Schwarz withdrew her application.
#5 Kevin Keck

Mr. Kennedy was recused due to a conflict of interest.

Kevin Keck appeared on his own behalf to request to proceed with Pharmacy Technician licensure.

Vice President Van Hassel opened the discussion by asking Mr. Keck why he was appearing in front of the Board.

Mr. Keck stated that he is applying for a pharmacy technician license and had to appear because of his charges.

Mr. Keck stated that he was charged with domestic violence and criminal trespassing. Mr. Keck stated that when he split up with his girlfriend he went to her house to pick up some items he wanted. He waited outside the house and was arguing with her on the phone and the cops were called. Mr. Keck stated that there was no fighting. Mr. Keck stated that he paid the fine and took the anger management classes. Mr. Keck stated that he currently works at Walgreens as a cashier.

On motion by Ms. Snair and seconded by Dr. Dang, the Board unanimously agreed to approve Mr. Keck’s pharmacy technician application.

#6 Camerina Gamboa-Ettel

Camerina Gamboa-Ettel appeared on her own behalf to request to proceed with Pharmacist Licensure.

President Kennedy opened the discussion by asking Ms. Gamboa-Ettel why she was appearing in front of the Board.

Ms. Gamboa-Ettel stated that she is a pharmacist licensed in Nevada and would like to reciprocate to Arizona.

Ms. Gamboa-Ettel stated that in 2012 she was disciplined by the Nevada Board for an incident that occurred in 2011.

Ms. Gamboa-Ettel stated that she was working for CVS pharmacy and had ACL surgery. Ms. Gamboa-Ettel stated that she was not comfortable taking CII medications. Ms. Gamboa-Ettel stated that she was still in pain and had no time off and was not able to get an appointment with her doctor. Ms. Gamboa-Ettel stated that she was filling a prescription for Lortabs for her mother and put in a few extra tablets than the prescription required. Ms. Gamboa-Ettel stated that she never picked the prescription up and a technician noticed that the bottle contained extra tablets when it was returned to stock.

Mr. Kennedy asked how many extra tablets were placed in the bottle. Ms. Gamboa-Ettel replied 20 tablets.

Ms. Gamboa-Ettel stated that she went to the PRN program for ethical issues for 5 years.
Mr. Kennedy asked about the unauthorized refills. Ms. Gamboa-Ettel stated that someone she knew from high school brought in a prescription and additional refills were not authorized. Ms. Gamboa-Ettel stated that she filled the prescription in 3 days.

Mr. Skvarla asked about filling controlled substance prescriptions for family members. Ms. Gamboa-Ettel stated that she filled her mother’s prescription.

Mr. Skvarla asked Ms. Gamboa-Ettel if she diverted or abused drugs. Ms. Gamboa-Ettel replied no.

Ms. Gamboa-Ettel stated that she is diligent in checking prescriptions for the date. Ms. Gamboa-Ettel stated that she has patients wait while she takes her time filling the prescriptions. Ms. Gamboa-Ettel stated that she does not fill prescriptions for family members and she takes her prescriptions to another pharmacy.

Mr. Skvarla asked Ms. Gamboa-Ettel why she wants to move to Arizona. Ms. Gamboa-Ettel stated that she has family that lives in Tucson.

Mr. Skvarla asked Ms. Gamboa-Ettel to describe the PRN program. Ms. Gamboa-Ettel stated that the program is for professionals addicted to alcohol or drugs. Ms. Gamboa-Ettel states that the program requires attendance at NA or AA meetings.

Mr. Skvarla asked Ms. Gamboa-Ettel if she abused controlled substances. Ms. Gamboa-Ettel stated that the Board recommended that she stay in the program.

Dr. Gandhi asked about the assessment. Ms. Gamboa-Ettel stated that she went for an assessment and it was recommended that she remain in the program for 5 years.

**Mr. Blaire placed a motion on the floor to approve the application and it was seconded by Mr. Kennedy.** The motion was withdrawn.

Mr. McAllister suggested that Ms. Gamboa-Ettel may want to withdraw her application and reapply when she can describe the situation.

Ms. Galvin stated that the Board could ask for additional information.

**On motion by Mr. Van Hassel and seconded by Dr. Dang,** the Board unanimously agreed to table the application until Ms. Gamboa-Ettel can provide documentation of performance and the final assessment from the PRN program.

**Jonathan Nomamiukor**

Jonathan Nomamiukor withdrew his application.
#8 Raghu Ram Earni

Raghu Ram Earni appeared on his own behalf to request to proceed with Pharmacist Licensure.

President Kennedy opened the discussion by asking Mr. Earni why he was appearing in front of the Board.

Mr. Earni stated that he is applying to reciprocate to Arizona from Oregon. Mr. Earni stated that he has the FPGEEC certificate and has a current H1B visa and would like to transfer the H1B to Arizona. Mr. Earni stated that he does have a job offer.

On motion by Mr. Kennedy and seconded by Mr. Van Hassel, the Board unanimously agreed to meet in Executive Session.

The Board returned from Executive Session.

Mr. Skvarla asked Mr. Earni why he wanted to move to Arizona. Mr. Earni stated that he would like to move for the warmer weather. Mr. Earni stated that he has worked for the same pharmacy for 12 years.

On motion by Mr. Skvarla and seconded by Ms. Snair, the Board approved Mr. Earni’s pharmacist application. There was a roll call vote. (Mr. Blaire – aye, Dr. Dang – aye, Mr. Minkus – nay, Mr. Skvarla – aye, Mr. Van Hassel – nay, Mr. Kennedy – aye, Ms. Locnikar – nay, and Ms. Snair – aye). The motion carries.

AGENDA ITEM 13 – Pharmacy Technician Trainee Reapply Requests – Expired Licenses

On motion by Ms. Snair and Dr. Dang, the Board approved the 40 pharmacy technician trainees reapply requests that have expired for an additional 2 years.

Mr. Van Hassel asked that a representative from Convergys be asked to appear at the Board Meeting to discuss applications being submitted.

AGENDA ITEM 14 – Reports

Executive Director

Dr. Gandhi passed out the financials.

Dr. Gandhi passed out a report on the number of licenses and permits issued.

Dr. Gandhi reviewed the bills currently being heard in the legislative sessions.

Dr. Gandhi stated that Mara Mellstrom is the new policy advisor to the Governor’s Office.
Deputy Director Report

Dr. Frush reviewed the Compliance Officers Activity Report and the Drug Inspector Report with the Board Members.

During the months of October and November, the Compliance Staff issued letters for the following violations:

**Pharmacy Violations**
1. Expired Rx and OTC products in Pharmacy 5
2. Hot water not working properly –2
3. Pharmacy Technician Trainee Compounding – 1
4. Technician Training Compounding program – 3 (Cannot compound until program is completed)
5. Pharmacy Technician offering Counseling – 3
6. Failure to ask for allergies and medical conditions – 1
7. Shared Services Notification to Patient – 1
8. Pharmacy Technician Trainee license expired – 3
9. Failure to have Policies and Procedures Manual – 1
10. Uncleanliness in Pharmacy – 3 (Dirty dishes, dirty shelves)
11. Media Fill Tests not completed – 3
12. Hood Certification - 1
13. No cold water – 1
14. Sneeze Barrier Broken - 1

**Controlled Substance Violations**
1. Controlled Substance Overage - 13
2. Controlled Substance Shortage - 14
3. Controlled Substance Inventory did not include 3-5 on Change of Pharmacist in Charge –2
4. Annual Controlled Substance Inventory not taken -2
5. CV Register not signed by the Pharmacist – 1
6. Failure to report PSE sales – 1
7. Controlled Substance Inventory not taken upon change of PIC – 2
8. Missing copies of DEA 222 forms – 1
9. Annual Controlled Substance Inventory not dated or signed – 1
10. Controlled Substance Inventory Not Available - 1
11. Controlled Substance Records Not Available - 1
12. Controlled Substance Inventory Incomplete – 1

**Documentation Violations**
1. Immunization Documentation - 20
2. Compounding Documentation -7
3. Daily sig log not signed – 5
4. Counseling documentation – 12
5. Mechanical Storage Device Documentation- replenishment, accuracy validation, and training - 3
Areas outside the pharmacy

1. Remodels must notify Board office and must be complete when asking for an inspection
2. If a pharmacist denies to fill a patient’s CII prescription, inform the patient why the prescription is not being filled

Complaints
6- pending assignment
3 – Investigations concerning alleged violations at pharmacies
6 – DEA 106 loss forms being investigated

A complaint will be opened against the pharmacy where the pharmacist was summarily suspended and will go to hearing. DEA is providing 106 forms and recall information. The pharmacy failed to notify the DEA and Board of the significant loss upon discovery.

PAPA Report – Schedule V

Deborah Marcum, PAPA administrator, was present to represent the PAPA program. Ms. Marcum stated that there are a total of twenty-nine (29) participants in the PAPA program. Ms. Marcum stated that one participant1 (1) has completed the program and one contract has been terminated.

The Board discussed the reporting of individuals that have been terminated for diversion. The Board decided that a reminder would be placed in the newsletter.

AGENDA ITEM 15 – PTCB Exam Presentation

Mariam Mobley Smith with PTCB gave a brief overview of the PTCB exam and the expanding roles of technicians.

AGENDA ITEM 16– Conferences – Schedule W

All Conferences have been recorded and can be viewed on our website. To view the conference discussions follow the steps below:
  1. Go to our Website – www.azpharmacy.gov
  2. Under Quick Links, click on Watch the latest Board Meeting video
  3. Click on January 25, 2017 Board Meeting and click on Afternoon Session.
  4. The conferences begin the Afternoon Session

Conference 1 – Complaint #4513

The following individuals were present to discuss the complaint:
1. Medhat Mettias – Respondent – Pharmacist In Charge (Telephonic)
2. David Robani – Respondent – Hallendale Pharmacy (Telephonic)
3. Roger Morris – Legal Counsel for Hallendale Pharmacy

President Kennedy opened the discussion by asking Hallendale to address the complaint.

The conference can be viewed on our website.
On motion by Mr. McAllister and seconded by Mr. Van Hassel, the Board unanimously agreed to dismiss the complaint.

Conference 2 – Complaint #4505

Mr. Skvarla was recused due to a conflict of interest.

Mr. Waggoner gave a brief overview of the complaint. The conference can be viewed on our website.

The following individuals were present to discuss the complaint:
1. Jessica Armaz – Respondent – Pharmacist
2. Joe Leyba – Witness – Pharmacy Director
3. Paul Wachter – Division director for Albertsons/Safeway

On motion by Mr. McAllister and seconded by Ms. Snair, the Board unanimously agreed to issue an advisory letter to the pharmacist concerning the final accuracy check of the prescription.

AGENDA ITEM 17– Consents – Schedule X

On motion by Mr. Van Hassel and seconded by Mr. Minkus, the Board unanimously agreed to accept the following consent agreement:
1. Maricopa Medical Center - 16-0027-PHR

Mr. Kennedy was recused due to a conflict of interest. On motion by Mr. McAllister and seconded by Mr. Skvarla, the Board unanimously agreed to accept the following consent agreement:
1. Marilyn Myers - 16-0024-PHR

AGENDA ITEM 18– Complaint Review – Consideration of Complaints on Schedule Y

President Kennedy opened the discussion by stating the Board Members would review all the complaints on schedule Y.

Complaint #4527 - Mr. Skvarla was recused due to a conflict of interest. On motion by Mr. Van Hassel and seconded by Mr. McAllister, the Board unanimously agreed to dismiss the complaint.

AGENDA ITEM 19 –Thomas Goebig – Stipulation to Continue Hearing Case No. 17-0005 – PHR

Mr. Skvarla was recused due to a conflict of interest.

President Kennedy stated that Mr. Goebig’s Legal Counsel have asked to continue the hearing until the next meeting. Mr. Kennedy stated that the Summary Suspension would remain in place.

On motion by Mr. Van Hassel and seconded by Mr. Minkus, the Board unanimously agreed to accept the stipulation to continue the hearing.
AGENDA ITEM 20 – Thomas Goebig – Case No. 17-0005 – PHR – Vacation of Hearing

Mr. Skvarla was recused due to a conflict of interest.

President Kennedy stated that since the Board has accepted the Stipulation to Continue the Hearing the Board must vacate the Hearing to be held tomorrow.

On motion by Mr. Van Hassel and seconded by Mr. Minkus, the Board unanimously agreed to vacate the Hearing.

AGENDA ITEM 21 – Hearings – Schedule Z

The Hearing scheduled to be held on January 26, 2017 was vacated.

AGENDA ITEM 22 – ASHP Antibiotic Stewardship – Dr. Dang

President Kennedy asked Dr. Dang to address this issue.

Dr. Dang stated at the ASHP midyear meeting they discussed the Antibiotic Stewardship. Dr. Dang stated that the antibiotic stewardship would lead to the adoption of the appropriate use of antimicrobials. Dr. Dang stated that the inappropriate use of antimicrobials has led to the spread of drug resistant organisms.

Dr. Dang asked if the Board should establish rules or regulations to implement the antibiotic stewardship. Dr. Dang stated that not all hospitals rely on joint commission which requires this stewardship.

Mr. McAllister stated that he feels that this is an overreach for the Board and suggested that the hospital is responsible to CSM.

The Board took no action at this time.

AGENDA ITEM 23 – NABP Interactive Member Forum – Dr. Dang and Mr. Blaire

President Kennedy asked Dr. Dang and Mr. Blaire to address this agenda item. Mr. Blaire stated that it was a very interesting meeting.

Mr. Blaire stated that the following topics were discussed:
1. Pharmacists dispensing oral contraceptives and naloxone
2. Tech check Tech
3. Prescription Monitoring Programs
4. Medical Marijuana
5. Compounding Regulations – Sterile Compounding and Sterile Product Blueprint

Mr. Blaire stated that they discussed the fact that there is no data comparing adverse events pre or post implementation of 797.
Mr. Blaire stated that they talked about licensing of 503 (B) facilities and that states should take a more active role. Mr. Blaire stated that a company can apply to the FDA to be licensed, but may not be inspected for one month to a year. Mr. Blaire noted that the FDA goes in after the company is established. Mr. Blaire noted that it would be up to the State to inspect prior to operation. Mr. Blaire noted that various States inspect differently. Some states inspect the environment and workflow prior to the FDA inspection and some states will not issue a license until the facility is inspected by the FDA.

Dr. Dang stated that they are trying to encourage health care professionals to utilize PMP programs.

Dr. Dang stated that there are a number of states approving the legalization of marijuana.

Dr. Dang stated that the Tech-check-Tech technology is evolving. Dr. Dang stated that ultimately the final product is verified by a pharmacist because the final check encompasses the utilization of the pharmacist’s clinical skills.

**AGENDA ITEM 24 – Permissionless Innovations Book**

Mr. McAllister stated that he asked Dr. Gandhi to purchase the book for the Board members because the Idaho Board reviewed the book.

Mr. McAllister stated that regulations are written looking back based on old ways of doing things.

Mr. Van Hassel stated that we should look at the telepharmacy rules and overprescribing.

Mr. Blaire stated that it is a great concept but we would need to weigh any potential problems that may occur.

Mr. Skvarla stated that he learned about being open minded but the Board must protect the patients. Mr. Skvarla stated that the concept would need more dialogue.

Dr. Dang stated that he believes in innovation and ways to enhance the profession. Dr. Dang stated that technology is great to improve workflow. Dr. Dang noted that the pharmacist’s clinical skills are irreplaceable.

Mr. Kennedy stated that it spurs the thought process.

**AGENDA ITEM 25 – Ownership Changes**

President Kennedy stated at this time the Board should reach out to other states and organizations to determine what they feel constitutes an ownership change and if the ownership change is different for different types of ownerships (LLC & Corporation)

**AGENDA ITEM 26 – Automated Storage and Distribution Systems**

President Kennedy asked for comment on this agenda item.

Mr. McAllister stated that this may pose a restriction of business if they can only be used in the long
term care setting. Mr. McAllister stated that the Board could further discuss this topic at the June meeting.

**On motion by Mr. Van Hassel and seconded by Dr. Dang,** the Board unanimously agreed to discuss this agenda topic at the June meeting.

**AGENDA ITEM 27 – Technology Assisted Verification of Product –**

President Kennedy stated that the committee has met twice and discussed the issues.

Ms. Snair stated that she would like to see a language change concerning the scanning of the bottle.

Mr. Skvarla stated that there needs to be some clarity around the technician performing the scanning because a case could be tried in civil court.

Dr. Dang stated that he feels a pharmacist should perform a final accuracy on the completed product.

Mr. McAllister stated that the final check of the product is still in place.

Dr. Dang stated that you lose a final critical accuracy check if a pharmacist does not check the final product.

Ms. Sparks (Fry’s) stated that the pharmacist would verify the DUR. The technology would verify that the correct product is scanned. Ms. Sparks stated that the pharmacist does have the option to look at the product.

Ms. Walmsley (Walgreens) stated that the pharmacist would review the data entry and the DUR. Ms. Walmsley stated that the technician would pass the product to another technician to reverify the product. Ms. Walmsley stated that the technicians must meet certain qualifications.

Ms. Snair stated that often two pharmacists verify the same product as a second check.

Dr. Dang stated that by eliminating the second check by a pharmacist it could eliminate the possibility of catching a mistake.

Mr. Kennedy stated that the pharmacist has the option to check again. Mr. Kennedy stated that the law does not preclude the pharmacist from doing the check.

Ms. Walmsley stated that in Iowa the pilot was a success. This process would allow the pharmacist to participate in patient care activities.

Ms. Galvin stated that they could open a docket and notice of proposed rule-making and have GRRC review the proposed rule. Ms. Galvin stated that the Board could also gather informal comments.

**On motion by Mr. Van Hassel and seconded by Mr. McAllister,** the Board decided to have an Informal session to gather public comments.
AGENDA ITEM 28 – NABP Annual Meeting – Selection of Delegate

On motion by Mr. Kennedy and seconded by Mr. Van Hassel, the Board unanimously agreed to offer the delegate position to a Board Member attending the meeting.


On motion by Mr. Van Hassel and seconded by Ms. Snair, the Board denied the pharmacy technician trainee application for Jessica Orange. There was one nay vote by Mr. Kennedy.

AGENDA ITEM 30 – Vanessa Thompson – Review of Evaluation and Pending Pharmacy Technician Trainee Application

Mr. Kennedy and Mr. Skvarla were recused due to a conflict of interest.

On motion by Mr. McAllister and seconded by Mr. Van Hassel, the Board denied the pharmacy technician trainee application for Vanessa Thompson.

AGENDA ITEM 31 – June Meeting at Arizona Pharmacy Association in Tucson

President Kennedy stated that the meeting in June would likely be a two day meeting and is not sure of the financial impact it would have on the Board.

The Board discussed the issue.

On motion by Mr. Van Hassel and seconded by Ms. Snair, the Board unanimously moved to have Board Staff review if it would be possible to hold the meeting in Tucson.

AGENDA ITEM 32 – Election of Officers

Mr. Van Hassel was elected as President and Mr. Blaire was elected as Vice President. Both individuals accepted the nomination.

AGENDA ITEM 33– Call to the Public

President Kennedy announced that interested parties have the opportunity at this time to address issues of concern to the Board; however the Board may not discuss or resolve any issues because the issues were not posted on the meeting agenda.

Roger Morris indicated that he would like the Board to discuss the Automated Dispensing Machines at a future meeting.

Kelly Fine stated that the Arizona Pharmacy Association is offering training for the dispensing of Naloxone. Ms. Fine stated that the Southwestern Clinical Meeting would be held in February.

Michael Rupp, MWU, discussed the issue of having a task force for prospective DURs.
Christine Cassetta addressed the 3PL bill and suggested a change to the language of the bill.

Lori Walmsley, President of the Arizona Pharmacy Association invited everyone to join the Association at Pharmacy Day at the Capitol on February 1, 2017.

AGENDA ITEM 34 – Future Agenda Items

1. NABP Blueprint
2. Convergys
3. PAPA – reporting by employers

AGENDA ITEM 35- Adjournment

There being no further business to come before the Board, President Kennedy adjourned the meeting at 4:30 P.M.